03/20/23 7:00 AMNYSE : BMY CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery ProgramsCHARM Therapeutics, a 3 D deep learning biotechnology company discovering and developing transformational medicines, today announced a strategic discovery collaboration with Bristol Myers Squibb for the identification and optimisation of compounds against Bristol Myers Squibb selected targets. “CHARM is excited to collaborate with Bristol Myers...RHEA-AIneutral
03/15/23 6:59 AMNYSE : BMY Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity CommitmentsBristol Myers Squibb today announced meaningful progress toward its global inclusion& diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule. In 2020, Bristol Myers Squibb and the Bristol Myers Squibb Foundation, an independent charitable organization, each committed $150 million over five years, totaling $300...RHEA-AIpositive
03/09/23 6:59 AMNYSE : BMY conferencesBristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023Bristol Myers Squibb will announce results for the first quarter of 2023 on Thursday, April 27, 2023. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or...RHEA-AIneutral
03/03/23 4:16 PMNYSE : BMY dividendsBristol Myers Squibb Announces DividendBristol Myers Squibb today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the$. 10 par value common stock of the company. About Bristol Myers Squibb Company. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.RHEA-AIneutral
03/03/23 8:00 AMNYSE : BMY Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb, a global biopharmaceutical company, to deploy an artificial intelligence algorithm and provider workflow software intended to identify and triage patients who may require further evaluation for the detection of...RHEA-AIneutral
03/03/23 6:59 AMNYSE : BMY Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta ThalassemiaBristol Myers Squibb today announced that the European Commission has granted full Marketing Authorization for Reblozyl ®, a first-in-class therapeutic option, for treatment in adult patients of anemia associated with non-transfusion-dependent beta thalassemia. Reblozyl is currently approved in the European Union, United States and Canada to...RHEA-AIpositive
03/02/23 6:59 AMNYSE : BMY clinical trialThe Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa InhibitorBristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa inhibitor. “The depth and breadth of the Librexia clinical development program will capture data in...RHEA-AIneutral
02/28/23 6:59 AMNYSE : BMY U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application and the European Medicines Agency has validated the Type II Variation Marketing Authorization Application for Opdivo ® as monotherapy in the adjuvant setting for the treatment of patients with completely...RHEA-AIneutral
02/28/23 6:59 AMNYSE : BMY conferencesBristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care ConferenceBristol Myers Squibb today announced that the company will take part in a fireside chat at Cowen’ s 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Head of Development, will answer questions about the company at 9:50 a.m. ET. Bristol Myers Squibb is a global biopharmaceutical...RHEA-AIneutral
02/27/23 6:59 AMNYSE : BMY conferencesBristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of CardiologyBristol Myers Squibb today announced the presentation of research supporting the company’ s cardiovascular franchise at the American College of Cardiology Annual Scientific Session& Expo together with the World Congress of Cardiology, taking place in-person and virtually March 4-6, 2023. During the meeting, the Bristol Myers Squibb-Pfizer Alliance...RHEA-AIneutral